We are a clinical stage biopharmaceutical company focused on delivering transformational medicines to patients with high unmet medical need. Our current focus is on advancing our lead program AKR-001 to provide a powerful new treatment for patients with NASH, a disease for which there are currently no marketed therapies.
Akero Therapeutics – developing efruxifermin (EFX) for NASH>
52 Week High
52 Week Low
Data Provided by Refinitiv. Minimum 15 minutes delayed.